-
Sulodexide
- indication:For the treatment of thrombosis. Also investigated for use/treatment in diabetic kidney disease, and neuropathy (diabetic).
- pharmacologypharmacology:
- mechanism: Thrombin inhibition produced by sulodexide is due to the additive effect of its components, namely, heparin cofactor II (HCII) catalysis by dermatan sulfate and antithrombin catalysis by fast moving heparin (FMH).
- toxicity:
- absorprion: Sulodexide is absorbed into the blood stream after oral dosing, the absorption rate being equivalent, either calculated from the fast-moving heparin fraction or from the dermatan fraction. Bioavailability following IM administration is approximately 90%.
- halflife: The elimination half-life was 11.7 +/- 2.0 h after intravenous administration, 18.7 +/- 4.1 h after 50 mg per os, and 25.8 +/- 1.9 h after 100 mg per os.
- roouteelimination:
- volumedistribution:
- clearance: